Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Uproleselan - GlycoMimetics

Next Previous
X
Search
Drug Profile

Uproleselan - GlycoMimetics

Alternative Names: APL-106; GMI-1271; Uproleselan injection - Apollomics/GlycoMimetics; Uproleselan sodium - GlycoMimetics

Latest Information Update: 04 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlycoMimetics
  • Developer Apollomics; GlycoMimetics; National Cancer Institute (USA); University of California, Davis
  • Class Antineoplastics; Antithrombotics; Glycolipids; Small molecules
  • Mechanism of Action E-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Gastrointestinal disorders
  • Phase I/II Acute biphenotypic leukaemia; COVID-19 pneumonia; Deep vein thrombosis; Myelodysplastic syndromes
  • No development reported Chronic myeloid leukaemia; Multiple myeloma; Solid tumours; Stem cell mobilisation

Most Recent Events

  • 04 Feb 2025 Updated efficacy, adverse event and pharmacodynamics data from a phase I/II trial presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 20 Dec 2024 Efficacy and adverse events data from phase-III bridging trial in Acute myeloid leukemia released byApollomics
  • 07 Dec 2024 Efficacy and adverse event data from a phase III trial in Acute myeloid leukemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top